Researchers say hepatitis B drug switch needed when resistance develops

01/30/2004 | Reuters

Chronic hepatitis B often gets treated with Epivir (lamivudine) but researchers found when resistance to it develops, patients seem to be better off using Preveon (adefovir) alone or in combination with lamivudine therapy. One researcher said there appears to be no reason, other than in instances of cirrhosis, for lamivudine to be used after beginning adefovir therapy in most cases.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Payer Marketing
Avalere Health
Washington, DC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX
Actuary
Meridian Health Plan
Detroit, MI
Chief Financial Officer
B. E. Smith
Miramar, FL